Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine Search
Considerations for biopharma under a first-inventor-to-file regime
Americas
The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system.   1 April 2013
Russia v Eurasia: national and regional differences in patentability
Asia
There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain.   1 April 2013
Twenty-one years of SPCs – a cause for celebration?
Big Pharma
Gordon Wright reviews the key SPC cases as Europe’s SPC Regulation for medicinal products approaches its 21st birthday.   28 March 2013
Americas
For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities.   28 March 2013
Big Pharma
The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.   28 March 2013
Big Pharma
When most people hear the word counterfeiting, they think of fashion, but as Bruce Longbottom of Eli Lilly and Company explains, drugs are a key target too.   28 March 2013
Americas
UK pharmaceutical company AstraZeneca has reached a settlement with Actavis and Egis Pharmaceuticals that delays the release of generic versions of its cholesterol treatment Crestor.   27 March 2013
Americas
AstraZeneca has signed a five-year licensing deal with Moderna Therapeutics, a US biotechnology company specialising in drugs using RNA therapeutics.   22 March 2013
Americas
Pharmaceutical companies Bayer, Intendis and Intraserv have filed a patent infringement lawsuit against Glenmark after it applied to market a generic version of rosacea treatment Finacea.   15 March 2013
Americas
Generic drug maker Mylan has struck a deal with pharma companies Shionogi and Andrx to resolve a patent dispute over their diabetes drug Fortamet.   15 March 2013